الفهرس 
Diabetes MellitusOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
Diabetic nephropathy (DN) is the major microvascular complications in diabetic patients. DN is a leading cause of morbidity and mortality, the accuracy of current tests in predicting the beginning, progression and response to various regimens for diabetic nephropathy is still dispute; and it has engendered a search for more specific and sensitive biomarkers. The current study aimed to evaluate the role of urinary liver fatty acid binding protein (u-LFABP) in the pathogenesis and progression of DN.
Seventy Egyptian subjects, including patients with type2 diabetes mellitus, diabetic nephropathy and diabetic kidney disease. Together with 20 normal control were enrolled in this study. Serum levels of interleukin-6 (IL-6), neuropeptide Y (NPY), and u-LFABP were measured. The lipid profile, kidney function tests including s-creatinine, u-creatinine, e-GFR, blood urea nitrogen (BUN), urinary albumin excretion rate (UAER). Also blood glucose and HbA1c were also analyzed.
The results showed elevation in the levels of u-LFABP, NPY, IL-6. Kidney function tests (except e-GFR and u-Cr were significantly decreased) and lipid profile parameters except HDL-c in diabetic nephropathy and DKD when compared to the control group.
u-LFABP may be used as an early useful promising biomarker with high sensitivity and specificity in diabetic nephropathy.